Shri Kapil Sibal, Union Minister for Science & Technology and Earth Sciences, while launching the DBT/Wellcome Trust India Fellowships, here today, stated that the new partnership would boost the biomedical research in India. He further added that the £80 million scheme – jointly funded by the Government of India's Department of Biotechnology (DBT) and the Wellcome Trust over 5 years – aims to strengthen the research base of Indian biomedical science by providing fellowship programmes to support researchers from newly-qualified senior researchers. The launch was also attended by Dr. M. K. Bhan, Secretary, Department of Biotechnology, and Dr Mark Walport, Director of the Wellcome Trust.
Myconostica, a UK-based medical diagnostic company which specialises in rapid and highly specific tests for life-threatening fungal infections, announced the launch of a new test to assist medical and scientific professionals identify the two most common causes of fungal pneumonia.
Drug maker Aurobindo Pharma has received tentative approval from US Food and Drug Administration to manufacture and market Abacavir Sulfate and Lamivudine tablets, used in the treatment of HIV (human immunodeficiency virus).
The Union Ministry of Finance has announced the anti-dumping duty imposed on the third generation parenteral cephalosporin antibiotic ceftriaxone sodium sterile imported from China as per the final recommendations of the Directorate-General of Anti-Dumping and Allied Duties (DGAD).
The total investment in special economic zones (SEZs) across the country is likely to touch around Rs 2.84 lakh crore by December 2009 and these SEZs are likely to create around 21 lakh additional jobs…[English]-[French]-[Spanish]
Zydus Cadila has received an approval from the US FDA to market Ramipril capsules in the strengths of 1.25 mg, 5 mg, and 10 mg. The drug falls in the anit-hypertensive segment. The sale of Ramipril capsules as per NDC was estimated at US$ 1.06 billion.
The U.S. Food and Drug Administration announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.
Biogen Idec and Elan Corp have launched the first clinical trial of their multiple sclerosis drug Tysabri for patients with relapsed or refractory multiple myeloma, the companies.
Smith & Nephew, a global medical technology business, specializing in Orthopaedic Reconstruction, Orthopaedic Trauma & Clinical Therapies, Endoscopy and Advanced Wound Management products and Smith & Nephew Orthopaedics KK Japan announced that it has received Japanese regulatory C1 Category Reimbursement approval for it's award winning OXINIUM oxidized zirconium technology.
Sandoz has received US Food and Drug Administration approval for its Omnitrope Pen 10 with liquid cartridge. Omnitrope, a somatropin, is approved for long-term treatment of paediatric patients who have growth failure and long-term replacement therapy in adults with growth hormone deficiency.
Roche Holding AG's DNA test is a safe and effective way to help gauge how well hepatitis B virus treatments are working, U.S. health regulators.
Pfizer Inc and Medivation, Inc announced that they have entered into an agreement to develop and commercialize Dimebon, Medivation’s investigational drug for treatment of Alzheimer’s disease and Huntington’s disease.
The U.S. Food and Drug Administration approved the first nucleic acid test for hepatitis B virus (HBV) that measures the amount of viral DNA (viral load) in a patient’s blood. Assessing a patient’s viral load provides health care professionals with a highly sensitive method for gauging the progress of antiviral therapy in patients with chronic HBV infections.
Antares Pharma, Inc, a specialty pharmaceutical company which focuses on improving pharmaceuticals through advanced drug delivery systems has entered into a development agreement with Dr Reddy's Laboratories, Inc for the development of an innovative, topically applied product, using Antares' ATD Gel platform, targeting specific receptor sites within the skin.
Dr Reddy's Laboratories (DRL) has announced a licensing and distribution agreement with Cosmederm Technologies (CT), a US-based specialty pharmaceutical company focused on dermatology and aesthetic medicine.
The Chennai-based Bafna Pharmaceuticals Ltd is planning to set up its marketing operations in the Sri Lankan pharma market for branded generics by registering product dossiers for lifestyle diseases. With this, the company which has been supplying generic products to the Sri Lankan market is shifting its focus to capture a share in the branded generic market.
Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies(R) against two targets in oncology and immunology and equally share the resulting profits.
Strides Arcolab, a Rs 725-crore plus Bangalore-based pharma giant, has received two ANDA approvals for Dexamethasone injection USP, 4mg/ml, and Dexamethasone Sodium Phosphate injection USP, 10 mg/ml.
Indian pharmaceutical market is likely to grow at 19.4 percent. The growth will be facilitated by health consciousness, affordability due to rising incomes of expanding middle class and also health insurance facilities, Confederation of Indian Industry (CII)- Interlink report says.
The US Food and Drug Administration (FDA) has issued a Complete Response letter to BioDelivery Sciences International (BDSI) for Onsolis – formerly known as BEMA Fentanyl, in the US.